[2]Richeldi L, Collard H R, Jones M G. Idiopathic pulmonary fibrosis[J]. The Lancet, 2017, 389(10082): 1941-1952.
[3]King Jr T E, Bradford W Z, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. New England journal of medicine, 2014, 370(22): 2083-2092.
[4]Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes[J]. Journal of leukocyte biology, 2005, 78(1): 14-26.
[5]Höhne K, Wagenknecht A, Maier C, et al. Pro-fibrotic effects of CCL18 on human lung fibroblasts are mediated via CCR6[J]. Cells, 2024, 13(3): 238.
[6]Zhu J, Jiang Q, Gao S, et al. IL20Rb aggravates pulmonary fibrosis through enhancing bone marrow derived profibrotic macrophage activation[J]. Pharmacological Research, 2024, 203: 107178.
[7]Calver J F, Parmar N R, Harris G, et al. Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis[J]. Journal of Biological Chemistry, 2024, 300(6): 107300.
[8]Liao H Y, Da C M, Liao B, et al. Roles of matrix metalloproteinase-7 (MMP-7) in cancer[J]. Clinical biochemistry, 2021, 92: 9-18.
[9]Wakamatsu K, Nagata N, Kumazoe H, et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis[J]. Respiratory investigation, 2017, 55(1): 16-23.
[10]Wang K, Ju Q, Cao J, et al. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J]. Medicine, 2017, 96(23): e7083.
[11]Lian N, Jin H, Zhu W, et al. Inhibition of glutamine transporter ASCT2 mitigates bleomycin-induced pulmonary fibrosis in mice[J]. Acta Histochemica, 2022, 124(8): 151961.
[12]Ahangari F, Price N L, Malik S, et al. microRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis[J]. JCI insight, 2023, 8(4): e158100.
[13]Peng D, Fu M, Wang M, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]. Molecular cancer, 2022, 21(1): 104.
